Canada Markets closed

Ionis Pharmaceuticals, Inc. (IONS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
44.23-0.05 (-0.11%)
At close: 04:00PM EDT
44.23 0.00 (0.00%)
After hours: 05:00PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • j
    I think $57.00 is shy of where it will go near term. I project mid to upper 60's by end of year.
  • g
    Morgan Stanley has assumed coverage on Ionis Pharmaceuticals Inc (NASDAQ: IONS) with an Overweight (previously Underweight) rating and a price target of $57 from $30 to capture the optionality in these near-term readouts.
  • J
    Something is brewing with IONS, possibly takeover target by big Pharma/Bio ?
  • F
    I see where skippy Klein is still selling his freebies. I remember when he first came on board with a big introduction by the Crooke. Ok, so now years later ions still has no profit making Antisense drugs. Remember darkouttonight informed you that Antisense was only good for targeting. Klein didn't believe it,
    so how much has ions lost in that time ? Dr. Dorr VP says I dare ya from darkouttonight. They say that the secretary replaced me. Nope wasn't fired... I was bought out...thank you Lilly. Greetings from old darkouttonight. Smile.
  • D
    yahoo data: growth next year -1000% ??? some great analysis...
  • B
    Insiders are buying.
  • s
    Go baby go!!!!!!
  • s
  • B
    This Bayer relationship was my reason for getting into IONS. The market for an anti-coagulant that prevents clotting without causing bleeding is enormous! Glad to finally see some results on it.
  • R
    Is there any news that can move this stock.
  • M
    Huh? Why the big jump today?
  • F
    Two consecutive days of big gains! Company still way undervalued considering all clinical programs, more than thousands of patents in the RNA/Antisense space and readouts in the nearer future. Do absolutely not agree that Ionis is no buyout candidate which was always argued referring to multiple partnerships which make it much more complicated for an acquiring company. BNTX and/or MRNA may be interested to add huge RNA expertise and a phenomenal patent library as well as IONS owned development programs without having an issue with other partnerships with pharmaceutical companies such as Astra Zeneca, BIIB, Novartis etc. Just a few thoughts.
    Long-term bullish!
  • b
    congrats to buyers <30
    will be starting position tomorrow and dips ..

    this is long term hold and will brought out ...

  • L
    Just heard that IONS got alerted at ( I hope it pushes us higher!
  • P
    No volume but up. Strange!!
  • j
    Alnylam up that's why
  • S
    I listened to the conference call. Following are my personal observations.

    The acquisition of Akcea will allow Ionis to benefit by using Akcea's commercial capabilities to get wholly owned Ionis products to market sooner and more profitably.

    Five ongoing phase 3 studies are progressing well, and a sixth is expected to start later this year.

    Ionis expects to present at least ten drugs for marketing applications (which I believe means requests for approval) in the next five years. Ionis showed a slide with eighteen drugs that are nearing the approval stage. I inferred from this that in the best case scenario they might have those eighteen drugs up for approval in the next five years.

    Several mentions of the drug delivery methods improving, which improves the effectiveness of drugs.

    A lot of catalysts in late 2020 and in 2021. I suggest that you review the slides from the conference call for specifics.

    They often referred to the virtual investor day (Dec. 7). I inferred from this that they have a lot to present on 12-7-20.

    I noticed that there were a lot of questions from a lot of analysts (compared to the past two conferences) during the Q & A. I think that showed a lot more interest than in the recent past.

    Ionis has a lot of cash (almost $2 billion). Spinraza alone generated $74 million in the third quarter. Ionis had $65 million in R&D in the third quarter, and they expect a substantial increase in the fourth quarter (they already received $75 million). Ionis expects to be "meaningfully profitable" in 2020.

    There were several mentions of advancing the Ionis owned pipeline (which I believe on average will be more profitable than drugs that are marketed by other companies).

    There was a lot of discussion of many (very many) individual drugs in the pipeline that are progressing well. I believe many of the existing drugs are being tested for additional illnesses. The beauty of this is that most of those drugs have already been tested for safety, so the approval process is shortened greatly. One drug is being tested in Brazil for Covid related issues. I am no expert, but the pipeline is so much greater than any other company I am familiar with.

    My personal opinion is that Ionis is greatly undervalued. They have money in the bank, they are not bleeding money, they have three successful drugs on the market, they have over forty drugs in the pipeline, etc. I am "hoping" that whatever is presented at the investor conference on 12-7-20 will give the stock a big boost.

    Any criticism of this post is appreciated.
  • W
    Since Ionis stock formed a grand scale inverse head & shoulder chart pattern in 2016, Ionis stock has been, with ups and downs, in an up trend. At the bottom of H&S, price was $20. Most recently, I mentioned “Ionis stock has a long journey to traverse crossing $200 mark and much higher”, here it will be literally “Time is money”. Market is not simple, so we still have to guard ourselves against overall market trend, political risks etc but Ionis and Akcea will stand out above all because Ionis has discovered drugs that treat etiologies of diseases, the first in the history of medicine, and the LICA drugs are practically side effect free or show only negligible risks, again never seen in medicine before, in most cases drugs that treat deadly diseases cause deadly side effects but LICA drugs have eliminated these! Market won’t ignore these facts, these are truly brilliant scientists, finally we got rid of doubters and “I know better” crowd. We still need a lot of patience.,
  • m
    Great article from IBD below in the news section of the IONS Yahoo Quote page. The article highlights what us Bulls on IONS have been posting for a couple years now. IONS is now ranked 8th out of the 500 Bio Stocks and has an RSR of 97 and a Composite rating of 94. IONS's earnings report absolutely BLEW AWAY estimates ( yes much of it was one time gains ) BUT there's much more to follow IMO. The best news is that IONS's Huntington's Disease drug could be approved in the next 12 months as could Wayliva. I thought the HD Drug was farther out than that.
    IONS is now a Leader in the Biotech Sector and as I posted many times IMO will be one of the best investments over the next 10 years. Finally IONS is getting the well deserved recognition it deserves.
    Over the next 3 years IMO IONS will have 3 to 4 new drugs on the market and a stock price of $200 to $250 a share.
    Where is GS now? Where are all the Bears on IONS that said Antisense was not a viable platform??? They have all gone into permanent hibernation.